Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 17.13 GBp
Change Today 0.00 / 0.00%
Volume 27.0K
As of 11:30 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

beximco pharmaceuti-gdr regs (BXP) Snapshot

Open
17.13 GBp
Previous Close
17.13 GBp
Day High
17.25 GBp
Day Low
17.13 GBp
52 Week High
09/23/14 - 20.38 GBp
52 Week Low
07/31/14 - 12.13 GBp
Market Cap
63.0M
Average Volume 10 Days
123.0K
EPS TTM
--
Shares Outstanding
367.9M
EX-Date
05/14/14
P/E TM
--
Dividend
0.01 GBp
Dividend Yield
4.46%
Current Stock Chart for BEXIMCO PHARMACEUTI-GDR REGS (BXP)

Related News

No related news articles were found.

beximco pharmaceuti-gdr regs (BXP) Related Businessweek News

No Related Businessweek News Found

beximco pharmaceuti-gdr regs (BXP) Details

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceuticals formulation products. Its formulation products comprise intravenous fluids and active pharmaceutical ingredients. The company offers its products covering various therapeutic categories, including antibiotics, gastro-intestinal, respiratory, analgesics and antipyretic, cardiovascular, anti-diabetics, allergic disorders, anti-infectives, central nervous system, cough and cold, endocrine, eye care, musculoskeletal, oncology, skin care, and vitamin and mineral supplements. It offers its products in various dosage forms, such as capsules, tablets, syrups, suspensions, injectables, sterile ophthalmic drops, nasal sprays, creams, ointments, intravenous fluids, metered dose inhalers, dry powder inhalers, suppositories, lyophilized injectables, prefilled syringes, etc. The company also provides contract manufacturing services for multinational and generic pharmaceutical companies. Beximco Pharmaceuticals Limited has a contract manufacturing agreement with GlaxoSmithKline for producing metered dose inhaler product. The company sells its products to retail outlets, medical institutions, and other pharmaceutical manufacturers in Bangladesh, Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia, Myanmar, Mauritius, Kenya, Ghana, Nigeria, Pacific Island, Latin and Central American countries, the Middle East, Central Asia, Singapore, Malaysia, the Philippines, Hong Kong, Germany, and Austria. Beximco Pharmaceuticals Limited was founded in 1976 and is headquartered in Dhaka, Bangladesh.

3,000 Employees
Last Reported Date: 07/24/14
Founded in 1976

beximco pharmaceuti-gdr regs (BXP) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

beximco pharmaceuti-gdr regs (BXP) Key Developments

Beximco Pharmaceuticals Limited Enters into New Loan Agreement with BHF-Bank Aktiengesellshaft to Fund Expansion

Beximco Pharmaceuticals Limited announced that it has entered into a new Loan Agreement with BHF-Bank Aktiengesellshaft, Frankfurt, Germany to borrow up to $51.559 million to partially finance the purchase of new plant and machinery to expand its production facilities in Dhaka, Bangladesh; it will be covered by Hermes (German Export Credit Agency Euler Hermes Aktiengesellshaft, Hamburg) guarantee. The Loan, which is secured on the plant and machinery being purchased, will be drawn down in four tranches against delivery and installation of the plant and machinery commencing now and due for completion in June 2016, with commissioning to be completed by September 2016. The Loan will attract interest at the rate of 2.25% per annum above LIBOR; in addition, the Lender will receive management fees and commitment fees. Repayment will be made over five years, in 10 semi-annual payments, commencing for $5.597 million from the earlier of six months after delivery and installation or 15 January 2016, with repayment of the balance commencing from the earlier of six months after commissioning or 30 March 2017.

Beximco Pharmaceuticals Limited Commences Export to Australia

Beximco Pharmaceuticals Limited announced the commencement of export to Australia, with the launch of Pantoprazole, a drug for treating gastrointestinal disorder. This is the first time a pharmaceutical product from Bangladesh has been exported to Australia.

Beximco Pharmaceuticals Limited Appoints Mr. Shah Monjurul Hoque as an Independent Non-Executive Director

Beximco Pharmaceuticals Limited announced that Mr. Shah Monjurul Hoque has been appointed to the company's Board as an Independent Non-Executive Director. Mr. Monjurul Hoque is a practicing lawyer in the Supreme Court of Bangladesh, both in the High Court Division and Appellate Division. Mr. Monjurul Hoque is the founder of Hoque & Associates. Mr. Monjurul Hoque has held various academic appointments in the field of law and has also acted as legal adviser to a number of corporate clients in Bangladesh and as the enlisted lawyer of several Bangladeshi banks.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BXP:LN 17.13 GBp 0.00

BXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BXP.
View Industry Companies
 

Industry Analysis

BXP

Industry Average

Valuation BXP Industry Range
Price/Earnings 11.1x
Price/Sales 1.5x
Price/Book 0.8x
Price/Cash Flow 11.1x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BEXIMCO PHARMACEUTI-GDR REGS, please visit www.beximco-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.